

National Vaccine Advisory Committee (NVAC) February 6, 2009 Meeting on the draft strategic National Vaccine Plan: Vaccine Industry and Researchers

Participants:

Cornelia Dekker	NVAC member and Moderator
Lance Gordon	NVAC member
Jaime Fergie	NVAC member
David Salisbury	NVAC liaison member, United Kingdom
Angela Shen	National Vaccine Program Office (NVPO)
Jovonni Spinner	NVPO
Dack Dalrymple	Dalrymple & Associates, LLC
Isabelle Claxton	GlaxoSmithKline (GSK)
John Herzog	GSK
Melia Sandler	HIDA
Amy Geller	Institute of Medicine
Chris Colwell	McKenna Long & Aldridge
George Curlin	NIH
Rebecca Sheets	NIH
Clem Lewin	Novartis
Shannon Dzubin	Novartis
Natalie Bolea	PhRMA
Mike Patel	sanofi Pasteur
Stuart Feldman	sanofi Pasteur
Margaret McCluskey	USAID
Laura York	Wyeth
Dean Mason	Wyeth

Telephone participants:

None

Summary Comments:

- Report card should be developed and implemented, e.g., companies compare current and future planned activities against the plan
- Funding and implementation critical – if USG commits to the importance of plan activities, as well as funds, then other stakeholders tend to follow (e.g. Pandemic Influenza)
- Political commitment/Higher ups – The group emphasized the importance of top level administration support of the plan.

- It was important to for the group see another round of the draft before it becomes final. Request for more time to get stakeholder input